Pfizer’s Dividend Yield Looks Almost Too Good. Here’s Why Management Isn’t Worried
Reuben Gregg Brewer, The Motley Fool
Sat, July 25, 2026 at 6:05 PM GMT+5:30
4 min read
- PFE
-0.16% - ^GSPC
+0.05% - NVDA
-0.92%
Pfizer (NYSE: PFE) has a shockingly high dividend yield of 6.8%. The S&P 500 Index (SNPINDEX: ^GSPC) has a 1% yield, and the average pharmaceutical stock‘s yield is roughly 1.5%. Given that huge disparity, it looks like Pfizer’s yield is too good to be true
There are reasons for the high yield that need to be monitored. However, management doesn’t seem too worried about the dividend. Here are some reasons why, and why you might want to buy ultra-high-yield Pfizer
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »
Pfizer’s management is focused on maintaining the dividend
Pfizer’s dividend, like all dividends, is paid at the discretion of the board of directors. That said, the company’s management team has been very clear about its support for the dividend. The dividend was mentioned directly on two slides in the first-quarter 2026 earnings presentation. One slide, focused on 2026 capital allocation priorities, stated that the company wants to “maintain and grow our dividend.” A second slide, directed at longer-term growth, made “maintain dividend” a stated goal.
If the board was actively considering cutting the dividend, management wouldn’t likely have mentioned the dividend on those two slides. Meanwhile, it is important to examine what supports the dividend. The answer isn’t earnings, which are under pressure right now, because a company’s dividend payments appear on its cash flow statement. The number is fairly large for Pfizer, with the first-quarter dividend payment totaling $2.445 billion. Annualize that, and you get nearly $10 billion
The company generated $2.6 billion from operating activities, which actually covers the dividend. However, the dividend isn’t the only thing the company has to pay for. After paying dividends, paying down debt, and investing in its business, the company’s cash balance at the end of the first quarter was higher than at the start. And not just a little higher, $560 million higher. The source of the extra cash was Pfizer selling long-term investments. Turning to the balance sheet, the company still has $11.3 billion in long-term investments, in addition to $1.7 billion in cash.
Watch Pfizer’s dividend, but there’s plenty to support it
This isn’t meant to suggest that investors should simply ignore the headwinds Pfizer is facing today. While the company looks capable of supporting the dividend, investors are worried about the pharmaceutical company’s future, which has pushed the stock lower and the yield higher. That said, most of the problems the company faces are normal for the pharmaceutical industry
